
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health Inc. is poised for robust growth, as evidenced by its projected $10-15 million sequential EBITDA improvements in both Q3 and Q4, setting a strong earnings trajectory with $32.5 million anticipated in Q3 and $45 million in Q4. The company's legacy Performance Suite Medical Expense Ratio is expected to enhance by 500 basis points to 89%, reflecting operational efficiency and cost management. Furthermore, with significant top-line growth expected for 2026 and a pathway to normalized margins of 7-10%, Evolent Health positions itself for outsized growth potential in the coming years, supported by its foundational strengths in value-based care and specialty services.
Bears say
The financial excerpts indicate a concerning outlook for Evolent Health, primarily due to a significant projected decline in revenue stemming from a loss of approximately $100 million from their legacy Performance Suite business. This revenue loss occurs amidst broader market challenges, as clients exit and rationalize their positions, which could exacerbate future earnings contraction. Furthermore, the company has downgraded its earnings per share estimates for FY2026 and FY2027, highlighting ongoing pressure on both profitability and operational efficiency.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares